# **VICLORIX<sup>®</sup>** Acyclovir

FORMS AND PRESENTATION viclorix® 400: Tablets: Box of 40. viclorix® 800: Tablets: Box of 40.

viclorix<sup>#</sup> 800: Tablets: Box of 40. COMPOSITION viclorix<sup>#</sup> 400: Each tablet contains Acyclovir 400mg. Viclorix<sup>#</sup> 800: Each tablet contains Acyclovir 800mg. Excipients: Microcrystalline Cellulose, Sodium Starch Gycollate, Colloidal Silicon dioxide, povidone (K30), Magnesium Stearate, Ferric Oxide (Acivir 400), FD & C ble lake #2 Indigo carmine AL30%-36% (Acivir 800). PHARMACOLOGICAL PROPERTIES

Pharmacodynamic properties Pharmacotherapeutic group: antiviral. ATC code: S01AD03

PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: antiviral.
ATC code: S01AD03
Acyclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity
against human herpse viruses, including herpse simplex virus (HSV) types I and II and
varicella zoster virus (VZV). The inhibitory activity of Acyclovir for HSV) I and HSV II and
VZV is highly selective. The enzyme thymidine kinase (TK) of normal, uninfected cells does
not use Acyclovir effectively as a substrate, hence toxicity to mammalian host cells is low;
however, TK encoded by HSV and VZV converts Acyclovir to rohymohsophate, a
nucleoside analogue which is further converted to the diphosphate and finally to the
triphosphate by cellular enzymes. Acyclovir is physophate interfrees with the viral DNA
polymerase and inhibits viral DNA replication with resultant chain termination following its
morporation into the viral DNA.
Prolonged or repeated courses of Acyclovir in severely immuno-compromised individuals may
result in the selection of virus strains with reduced sensitivity, which may not respond to
continued Acyclovir rement. Most of the clinical isolates with reduced sensitivity have been
relatively deficient in viral TK, however, strains with altered viral TK or viral DNA
polymerase have also been reported. *In vitro* exposure to Acyclovir therapy is not clear.
Pharmacokinetic properties
Acyclovir is only partially absorbed from the gut. Mean steady state peak plasma
concentrations (C\*max) following doses of 400 mg and ministered four-hourly were 8 microMol (1.8 µg/ml) and 9 microMol (1.6 µg/ml).
Corresponding C\*max levels following doses of 400 mg and abit mustalent C\*min
levels were 2.7 microMol (0.6 µg/ml) and 4 microMol (0.9 µg/ml).
Corresponding C\*max levels following doses of 400 mg and 800 mg administered four-hourly
were 5 microMol (1.0 µg/ml) and 8 microMol (0.0 µg/ml).
Corresponding C\*max levels following doses of 400 mg and 800 mg administered four-hourly
were 5.microMol (1.0 µg/ml) and 9 microMol (0.5 µg/ml) respr

The prophysics of herpes simplex infections in immunocompromised patients.
 The treatment of varicella infection) and herpes zoster (shingles) infections.
 The treatment of varicella infections in immunocompromised patients.
 The reatment of varicella infection).
 The suppression (prevention of frequences) of recurrent herpes simplex infections in immunocompromised patients.
 The treatment of varicella infection).
 The suppression (prevention).
 Total chicken pox (varicella infection).
 Total singles (herpes zoster infection).
 CONTRAINDICATIONS
 Viclorix<sup>4</sup> is contraindicated in patients known to be burgers.

Victorix<sup>®</sup> is contra-indicated in patients known to be hypersensitive to acyclovir or valacyclovir, or to any of the excipients. **PRECAUTIONS** Use in national set of the excipients.

ability to operate machinery PREGNANCY AND LACTATION

There have been no studies to investigate the effect of acyclovir on driving performance or the ability to operate machinery.
PREGNANCY AND LACTATION
Pregnancy
The use of acyclovir should be considered only when the potential benefits outweigh the
possibility of unknown risks.
A post-marketing acyclovir pregnancy registry has documented pregnancy outcomes in
increase in the number of birth defects amongst Viclorix\* exposed subjects compared with the
general population, and any birth defects showed no uniqueness or consistent pattern to
suggest a common cause. Systemic administration of acyclovir in internationally accepted
standard tests did not produce embryotoxic or teratogenic effects in rabibits, rats or mice. In a
non-standard test in rats, foetal abnormalities were observed but only following such high
subcutaneous doses that maternal toxicity was produced. The clinical relevance of these
findings is uncertain.
Caution should however be exercised by balancing the potential benefits of treatment against
mypossible hazad.
Prest-feeding:
Caution should however be exercised by balancing the potential benefits of treatment against
mypossible hazad.
Rest-feeding:
Acyclovir is eliminated primarily unchanged in the urine via active renal tubular secretion.
Any drugs administered concurrently that compete with this mechanism may increase
acyclovir plasma concentrations. Probenecid and cimetificine increase the AUC of acyclovir b
this mechanism, and reduce acyclovir renal clearance. Similarly increases in plasma AUCs of
acyclovir.
An experimental study on five male subjects indicates that concomitant therapy with acyclovir
increases AUC of tally administered theophylline with approximately 50%. It is recommende
to to mosure plasma concentrating concentrations during concomitant therapy with acyclovir
increases AUC of tally administered theophylline with approximately 50%. It is recommende
to the out of 1/100, are 1/100, and <1/10, uncommon ≥1/1000 and
<1/100, are 2/10,000 and
<1/100, are 2/10,000 and
<1/100, are 2

OV11 Common: Headache, dizziness. Yery rare: Agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, somolence, encephalopathy, coma. The above events are generally reversible and usually reported in patients with renal impairment or with other predisposing factors. **Repiratory, thoracic and mediastinal disorders:** Rare: Dyspoca. **Gastrointestinal disorders:** Common: Nausea, voniting, diarrhoea, abdominal pains. **Hepato-biliary disorders:** Common: Nausea, voniting, diarrhoea, abdominal pains. **Hepato-biliary disorders:** Keyr are: Reversible rises in bilimbin and liver related enzymes. Yery rare: Hepatitis, jaundice. **Skin and subcutaneous tisue disorders:** Common: Pruritus, rashes (including photosensitivity). *Uncommon:* Utricaria. Accelerated diffuse hair loss. Rare: Angioedema **Renal and urinary disorders:** Rare: Increases in blood urea and creatinine. Yery rare: Acute renal failure, renal pain. Renal and urinary disorders: Common: Fatigue, fever. **General disorders and administration site conditions:** Common: Fatigue, fever. **Reporting of suspected adverse reactions** Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product is important. It allows warming ouk/eyellowcard **DOSAGE AND ADMINISTRATION** Vidors' tablets may be dispersed in a minimum of 50 ml of water or swallowed whole with a little water. Ensure that patientis on high doss of acyclovir are adequately hydrated. <u>Dosage in adults</u> Hepressimplex infection:

<u>Horses in adults</u> <u>Herres simplex infection</u>: Treatment of herpes simplex infections: 200mg 5 times a day at 4 hourly intervals for 5 days. Prevention of herpes simplex infection: 200mg 4 times a day at 6 hourly intervals for 6-12

months. Prevention in immunocompromised patients: 200mg 4 times a day at 6 hourly intervals for the

-rrevenuon in immunocompromised patients: 200mg 4 times a day at 6 nourly intervals for the period that the patient is at risk.
 -In severely impaired Kidney function: 200mg twice a day at 12 hourly intervals.
 -In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut the dose can be increased or alternatively intravenous dosing could be considered.

could be considered. Dosing should begin as early as possible after the start of an infection; for recurrent episodes this should preferably be during the proformal period or when lesions first appear. -Suppression of herpes simplex infections in immunocompetent patients: Many patients may be conveniently managed on a regimen of 400 mg Viclorix<sup>®</sup> twice daily at approximately 12 hourdy intervals.

-Suppression of herrées simplex infections in immunocompetent patients: Many patients may be conveniently managed on a regimen of 400 mg Viclorix\* twice daily at approximately 12 hourly intervals.
 Dosage titration down to 200 mg Viclorix\* taken thrice daily at approximately eight-hourly intervals or even twice daily at approximately twelve-hourly intervals may prove effective.
 Some patients may experience break-through infection on total daily doses of 800 mg Viclorix\* Therapy should be interrupted periodically at intervals of six to twelve months, in order to observe possible changes in the natural history of the disease.
 -Prophylaxis of herpes simplex infections in immunocompromised patients: In severely immunocompromised patients (e.g. after marrow transplant) or in patients with impaired absorption from the gut, the dose can be doubled to 400 mg Viclorix\*, or alternatively, intravenous dosing could be considered.
 The duration of prophylactic administration is determined by the duration of the period at risk. Herpes zoater infections:
 -Treatment: 800 mg Viclorix\* should be taken 5 times daily at approximately 4 hourly intervals.
 -Treatment in patients with moderately impaired Kidney function: 800mg 3 times a day at 6-8 hourly intervals.
 -Treatment in patients with severely impaired Kidney function: 800mg twice a day at 12 hourly intervals.
 -Dassey functions:
 -Treatment in patients with severely impaired Kidney function: 800mg twice a day at 12 hourly intervals.
 -Dassey functions in immunocompromised patients should be given to intravenous dosing.
 Dosing should begin as early as possible after the start of an infection. Treatment of herpes simplex infections, and prophylaxis of herpes simplex infections in the immunocompromised patient (e.g. after marrow transplant) or in patients with impaired beter results if inititated as soon as possible after the onst

Treatment should continue for 5 days. Dosing may be more accurately calculated as 20 mg/kg bodyweight (not to exceed 800 mg) Viclorix<sup>®</sup> four times daily. No specific data are available on the suppression of herpes simplex infections or the treatment of herpes zoster infections in immunocompetent children. <u>Dosage in the elderly</u>: Dosage may be reduced in the elderly, especially in those kidneys are not working properly. The possibility of renal impairment in the elderly must be considered and the dosage should be adjusted accordingly (see Dosage in renal impairment below). Adequate hydration of elderly patients taking high oral doses of acyclovir should be maintained. <u>Dosage in renal impairment</u>:


maintained. Dosage in renal impairment: Caution is advised when administering acyclovir to patients with impaired renal function. Adequate hydration should be maintained. In the management of herpes simplex infections in patients with impaired renal function, the recommended oral doses will not lead to accumulation of acyclovir above levels that have been established safe by intravenous infusion. In the treatment of herpes zoster infections it is recommended to adjust the dosage to 800 mg acyclovir three times daily at approximately twelve - hourly intervals for patients with severe renal impairment (creatinine clearance less than 10 ml/minute), and to 800 mg acyclovir three times daily at intervals of approximately eight hours for patients with moderate renal impairment (creatinine clearance in the range 10 – 25 ml/minute).

## OVERDOSAGE

OVERDOSAGE Acyclovir is only partly absorbed in the gastrointestinal tract. Patients have ingested overdoses of up to 20g acyclovir on a single occasion, usually without toxic effects. Accidental, repeated overdoses of oral acyclovir over several days have been associated with gastrointestinal effects (such as nausea and vomiting) and neurological effects (headache and confusion). Overdosage of intravenous acyclovir has resulted in elevations of serum creatinine, blood urea nitrogen and subsequent renal failure. Neurological effects including confusion, hallucinations, agitation, seizures and coma have been described in association with intravenous overdosage. Management: patients should be observed closely for signs of toxicity. Haemodially sis significantly enhances the removal of acyclovir from the blood and may, therefore, be considered a management option in the event of symptomatic overdose.

STORAGE CONDITIONS Store below 30°C. Keep in original pack in intact conditions.

Date de revision: September 2014.



Union of Arab Pharmacis